<DOC>
	<DOC>NCT01341353</DOC>
	<brief_summary>The mainstay of treatment for atrial fibrillation remains pharmacological;however,catheter ablation has increasingly been used over the last decades. The relative merits of each strategy have not been extensively studied. Our study was designed to determine if catheter ablation is a feasible option as first-line therapy for treating patients with symptomatic AF.</brief_summary>
	<brief_title>Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>1 Patients with symptomatic AF recorded by ECG or Holter 2 Age:1875 years 3 Patients who are willing to enroll in the trial 1 Patients accompanied hyperthyroidism 2 Patients with sever liver or renal dysfunction 3 Patients with sever cardiac dysfunction 4 Patients had previous radiofrequency catheter ablation in the LA or Maze surgical procedure 5 Patients with emboli in atrium 6 Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>